ATE401071T1 - Verwendungen und zusammensetzungen für selektive krebs-chemotherapie - Google Patents

Verwendungen und zusammensetzungen für selektive krebs-chemotherapie

Info

Publication number: ATE401071T1
Authority: AT; Austria
Prior art keywords: compositions; cancer chemotherapy; selective cancer; vitamin; selective
Prior art date: 1999-08-30

Application number

AT99945197T

Other languages

English (en)

Inventor

Raxit Jariwalla

Original Assignee

Ester C Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-30

Filing date

1999-08-30

Publication date

2008-08-15

1999-08-30 Application filed by Ester C Company filed Critical Ester C Company

2008-08-15 Application granted granted Critical

2008-08-15 Publication of ATE401071T1 publication Critical patent/ATE401071T1/de

Links

239000000203 mixture Substances 0.000 title abstract 4
238000002512 chemotherapy Methods 0.000 title abstract 2
206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 4
229940072107 ascorbate Drugs 0.000 abstract 2
235000010323 ascorbic acid Nutrition 0.000 abstract 2
239000011668 ascorbic acid Substances 0.000 abstract 2
229910052500 inorganic mineral Inorganic materials 0.000 abstract 2
239000011707 mineral Substances 0.000 abstract 2
150000003700 vitamin C derivatives Chemical class 0.000 abstract 2
230000000973 chemotherapeutic effect Effects 0.000 abstract 1
238000001990 intravenous administration Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
210000004881 tumor cell Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)

AT99945197T 1999-08-30 1999-08-30 Verwendungen und zusammensetzungen für selektive krebs-chemotherapie ATE401071T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US1999/019449 WO2001015692A1 (en)	1999-08-30	1999-08-30	Methods and compositions for selective cancer chemotherapy

Publications (1)

Publication Number	Publication Date
ATE401071T1 true ATE401071T1 (de)	2008-08-15

Family

ID=22273462

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99945197T ATE401071T1 (de)	1999-08-30	1999-08-30	Verwendungen und zusammensetzungen für selektive krebs-chemotherapie

Country Status (16)

Country	Link
US (1)	US20040092549A1 (de)
EP (1)	EP1124550B9 (de)
JP (1)	JP2003508437A (de)
CN (1)	CN1165301C (de)
AT (1)	ATE401071T1 (de)
AU (1)	AU783283B2 (de)
CA (1)	CA2348565A1 (de)
CY (1)	CY1108293T1 (de)
DE (1)	DE69939123D1 (de)
DK (1)	DK1124550T3 (de)
ES (1)	ES2310941T3 (de)
NO (1)	NO326995B1 (de)
NZ (1)	NZ511396A (de)
PT (1)	PT1124550E (de)
TW (1)	TWI245643B (de)
WO (1)	WO2001015692A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001280448B8 (en) *	1998-01-05	2008-05-29	The Ester C Company	Vitamin C Compositions
US6878744B2 (en) *	1999-02-05	2005-04-12	Oxycal Laboratories, Inc.	Vitamin C compositions
EP1282416A2 (de) *	2000-05-19	2003-02-12	Progenics Pharmaceuticals, Inc.	Dehydroascorbinsäure-formulierungen und deren verwendungen
US6468980B1 (en) *	2000-09-01	2002-10-22	Oxycal Laboratories, Inc.	Methods and compositions for potentiating cancer chemotherapeutic agents
CA2420548A1 (en) *	2001-06-26	2003-01-09	Oxycal Laboratories, Inc.	Composition comprising vitamin c and a pyrone or furanone compound
GB0212405D0 (en) *	2002-05-29	2002-07-10	Insignion Holdings Ltd	Composition and its therapeutic use
PL2052273T3 (pl) *	2006-08-18	2012-08-31	Ge Healthcare As	Obrazowanie lub spektroskopia metodą rezonansu magnetycznego 13C śmierci komórkowej
AU2009304542A1 (en) *	2008-10-15	2010-04-22	Xingnong Wang	Use of tetrose to inhibit cancer and to increase cell viability
WO2014070769A1 (en)	2012-10-29	2014-05-08	The University Of North Carolina At Chapel Hill	Methods and compositions for treating mucosal tissue disorders
US20210283095A1 (en) *	2020-03-11	2021-09-16	Harold E. Siess	Detection and Treatment of Viral Diseases and Cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4822816A (en) *	1987-04-10	1989-04-18	Oxycal Laboratories, Inc.	Compositions and methods for administering vitamin C
GB2208798B (en) *	1987-07-20	1991-06-05	Norsk Hydro As	Anti-cancer agent comprising l-ascorbic acid and o-benzylidene-l-ascorbic acid or deuterated derivative
WO1990012571A1 (en) *	1989-04-07	1990-11-01	Oxycal Laboratories, Inc.	Compositions and methods for administering vitamin c
DE68928488T2 (de) *	1988-09-19	1998-04-02	Oxycal Lab Inc	Zusammensetzungen und verabreichungsverfahren für heilmittel
US5626883A (en) *	1994-04-15	1997-05-06	Metagenics, Inc.	Ascorbic acid compositions providing enhanced human immune system activity
KR100266373B1 (ko) *	1997-01-06	2000-09-15	더블유. 유 병	김치의 제조방법
AU744584B2 (en) *	1998-02-06	2002-02-28	Ester C Company, The	Stable liquid mineral ascorbate compositions and methods of manufacture and use

1999
- 1999-08-30 JP JP2001519906A patent/JP2003508437A/ja not_active Ceased
- 1999-08-30 NZ NZ511396A patent/NZ511396A/en not_active IP Right Cessation
- 1999-08-30 DK DK99945197T patent/DK1124550T3/da active
- 1999-08-30 AT AT99945197T patent/ATE401071T1/de not_active IP Right Cessation
- 1999-08-30 CN CNB998139181A patent/CN1165301C/zh not_active Expired - Fee Related
- 1999-08-30 US US09/830,912 patent/US20040092549A1/en not_active Abandoned
- 1999-08-30 AU AU57853/99A patent/AU783283B2/en not_active Ceased
- 1999-08-30 WO PCT/US1999/019449 patent/WO2001015692A1/en not_active Ceased
- 1999-08-30 CA CA002348565A patent/CA2348565A1/en not_active Abandoned
- 1999-08-30 ES ES99945197T patent/ES2310941T3/es not_active Expired - Lifetime
- 1999-08-30 DE DE69939123T patent/DE69939123D1/de not_active Expired - Lifetime
- 1999-08-30 EP EP99945197A patent/EP1124550B9/de not_active Expired - Lifetime
- 1999-08-30 PT PT99945197T patent/PT1124550E/pt unknown
- 1999-09-23 TW TW088116389A patent/TWI245643B/zh not_active IP Right Cessation
2001
- 2001-04-25 NO NO20012027A patent/NO326995B1/no not_active IP Right Cessation
2008
- 2008-08-25 CY CY20081100910T patent/CY1108293T1/el unknown

Also Published As

Publication number	Publication date
US20040092549A1 (en)	2004-05-13
DK1124550T3 (da)	2008-11-17
EP1124550A1 (de)	2001-08-22
CY1108293T1 (el)	2014-02-12
NZ511396A (en)	2003-08-29
ES2310941T3 (es)	2009-01-16
JP2003508437A (ja)	2003-03-04
EP1124550B9 (de)	2008-11-05
TWI245643B (en)	2005-12-21
NO326995B1 (no)	2009-03-30
EP1124550A4 (de)	2002-08-21
NO20012027L (no)	2001-06-20
CN1165301C (zh)	2004-09-08
PT1124550E (pt)	2008-08-29
AU783283B2 (en)	2005-10-13
CN1329489A (zh)	2002-01-02
EP1124550B1 (de)	2008-07-16
CA2348565A1 (en)	2001-03-08
NO20012027D0 (no)	2001-04-25
DE69939123D1 (de)	2008-08-28
WO2001015692A1 (en)	2001-03-08
WO2001015692A8 (en)	2001-10-11
AU5785399A (en)	2001-03-26

Legal Events

Date

Code

Title

Description

2008-12-15

UEP

Publication of translation of european patent specification

Ref document number: 1124550

Country of ref document: EP

2011-05-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE401071T1 (de)	2008-08-15	Verwendungen und zusammensetzungen für selektive krebs-chemotherapie
NZ526560A (en)	2004-12-24	Method of treating certain cancers using an estrogen agonist/antagonist
ATE295347T1 (de)	2005-05-15	Stoffe und zusammensetzungen für die verabreichung aktiver substanzen
BR0207378A (pt)	2004-06-15	Tratamento de câncer
MY139226A (en)	2009-08-28	Compositions and methods for wt1 specific immunotherapy
NZ711695A (en)	2017-05-26	Nanoparticle comprising rapamycin and albumin as anticancer agent
GR3017122T3 (en)	1995-11-30	Quinazolines derivatives for enhancing antitumor activity.
BG106738A (en)	2003-02-28	A method for chemoprevention of prostate cancer
WO2002030465A3 (en)	2003-03-13	Compositions that inhibit proliferation of cancer cells
MXPA02010866A (es)	2003-07-14	Composiciones y metodos para proteger celulas durante la quimioterapia y radioterapia contra el cancer.
ATE361668T1 (de)	2007-06-15	Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung
EP1007553A4 (de)	2004-09-22	Toxinrezeptoren aus zonula occludens
GB9816616D0 (en)	1998-09-30	Metalloproteinase inhibitors
CY1108787T1 (el)	2014-04-09	Συνθεση για ενισχυση χημειοθεραπευτικων παραγοντων καρκινου
FR2786398B1 (fr)	2002-12-27	Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide
TR200302193T4 (tr)	2004-02-23	Kombinasyon kemoterapisi.
DE69920506D1 (de)	2004-10-28	Chemotherapeutische zusammensetzung und verfahren
IL161444A0 (en)	2004-09-27	A process for the preparation of the 14beta-hydroxy-baccatin iii-1,14-carbonate
UA43624A (uk)	2001-12-17	Спосіб хіміотерапії раку яєчників
IT1313593B1 (it)	2002-09-09	Derivati di 1,2-diidro-1-oxo-pirazino 1,2-a indolo.
UA49562A (uk)	2002-09-16	Спосіб профілактики лімфогенних метастазів
Chadwick	1996	Aitik plans for the Twentyfirst century
WO2000078359A3 (en)	2002-01-24	Compositions for treating chemotherapy-resistant tumor cells
ZA200308829B (en)	2004-07-15	"The provision of support in underground mine workings".
ITMI932377A1 (it)	1995-05-09	Composizioni terapeutiche ad attivita' antitumorale a base di derivati 1,3,8,10 tetrasostituiti del 4,5,6,7-tetratiocino-(1,2-b: 3,4-b')-